R Stephanie Huang, PhD
Professor, Department of Experimental and Clinical Pharmacology (ECP)

Contact Info
Professor, Department of Experimental and Clinical Pharmacology (ECP)
Faculty, MS and PhD Programs in Molecular Pharmacology and Therapeutics (MPaT)
Fellow, Clinical Pharmacology and Pharmacogenomics, University of Chicago, IL
PhD Clinical Pharmacy, Department of Pharmacy Practice, Purdue University, IN
MS Clinical Pharmacy, Department of Pharmacy Practice, Purdue University, IN
BS Pharmacy, School of Pharmacy, Shanghai Medical University, Shanghai, P.R. China
Summary
Dr. Huang is a Tenured Professor at the Department of Experimental and Clinical Pharmacology, University of Minnesota. She is also an Associate Director for the Institute of Personalized Medicine | Pharmacogenomics U of M Alliance (PUMA-IPM) and a member of the Masonic Cancer Center at the University of Minnesota. She is a member of American Association for Cancer Research (AACR), American Society of Human Genetics (ASHG), and American Society of Clinical Pharmacology and Therapeutics (ASCPT). She serves on the editorial board of Annals of Translational Medicine and Frontiers in Pharmacology. To date, she has published over 90 peer-reviewed research papers many of which are in high caliber journals, e.g., Nature, Nature Medicine, PNAS, Blood, Cancer Research, Genome Biology and American Journal of Human Genetics. Dr. Huang is a board certified clinical pharmacologist with extensive training in genetics, molecular and cell biology, clinical trials and high throughput data analysis.
Expertise
pharmacogenomics, cancer chemotherapy, miRNA, computational biology
Awards & Recognition
Professional Associations
AACR, ASHG, ASCPT
Languages
Research
Research Summary/Interests
Pharmacogenomics and computational biology
Research Methods/Techniques
Research Funding Grants
Avon Foundation research grant
Publications
1. Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol. 2014 Mar 3;15(3):R47. PubMed PMID: 24580837; PubMed Central PMCID: PMC4054092.
2. Geeleher P, Andrey Loboda, Divya Lenkala, Fan Wang, Bonnie LaCroix, Sanja Karovic, Jacqueline Wang, Michael Nebozhyn, Michael Chisamore, James Hardwick, Michael L. Maitland and Huang RS. Predicting response to histone deacetylase inhibitors using high-throughput genomics. JNCI. 2015. 107(11): doi: 10.1093/jnci/djv247. PMID: 26296641. PubMed Central PMCID: PMC4643634.
3. Geeleher P, Cox NJ and Huang RS. Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models. Genome Biology. 2016. 17(1):190. PMID: 27654937. PMCID: PMC5031330.
4. Geeleher P, Zhang Z, Wang F, Gruener RF, Nath A, Morrison G, Bhutra S, Grossman RL, and Huang RS. Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies. Genome Res. 2017. Epub ahead of print. PMID: 28847918.
5. Geeleher P, Gamazon ER, Seoighe C, Cox NJ and Huang RS. Consistency in large pharmacogenomic studies. Nature. 2016. 540 (7631): E1-E2. PMID: 27905415.
6. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9758-63. PubMed PMID: 17537913; PubMed Central PMCID: PMC1887589.
7. Ziliak D, O'Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, Shukla S, Das S, Cox NJ, Vokes EE, Cohen EE, Dolan ME, Huang RS. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011 May;157(5):265-72. PubMed PMID: 21497773; PubMed Central PMCID: PMC3079878.
8. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Mi S, O'Donnell PH, Fraiman YS, Das S, Cox NJ, Lu Y, Macgregor S, Goode EL, Vierkant RA, Fridley BL, Hogdall E, Kjaer SK, Jensen A, Moysich KB, Grasela M, Odunsi K, Brown R, Paul J, Lambrechts D, Despierre E, Vergote I, Gross J, Karlan BY, Defazio A, Chenevix-Trench G, Dolan ME. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011 Aug 15;17(16):5490-500. PubMed PMID: 21705454; PubMed Central PMCID: PMC3160494.
9. Weng L, Ziliak D, Im HK, Gamazon ER, Philips S, Nguyen AT, Desta Z, Skaar TC, Flockhart DA, Huang RS. Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation. Ann Oncol. 2013 Jul;24(7):1867-73. PubMed PMID: 23508821; PubMed Central PMCID: PMC3690911.
10. Gamazon ER, Ziliak D, Im HK, LaCroix B, Park DS, Cox NJ, Huang RS. Genetic architecture of microRNA expression: implications for the transcriptome and complex traits. Am J Hum Genet. 2012 Jun 8;90(6):1046-63. PubMed PMID: 22658545; PubMed Central PMCID: PMC3370272.
11. LaCroix B, Gamazon ER, Lenkala D, Im HK, Geeleher P, Ziliak D, Cox NJ, Huang RS. Integrative analyses of genetic variation, epigenetic regulation, and the transcriptome to elucidate the biology of platinum sensitivity. BMC Genomics. 2014 Apr 16;15:292. PubMed PMID: 24739237; PubMed Central PMCID: PMC3996490.
12. Lenkala D, LaCroix B, Gamazon ER, Geeleher P, Im HK, Huang RS. The impact of microRNA expression on cellular proliferation. Hum Genet. 2014 Jul;133(7):931-8. PubMed PMID: 24609542.
13. Wang Fan, Chang Jeremy, Kao Chester, and Huang RS. High expression of miR-532-5p, a tumor suppressor, leads to better prognosis in ovarian cancer both in vivo and in vitro. Molecular Cancer Therapeutics, 2016. 15(5): 1123-1131. PMID: 26873729. PMCID: PMC4873383.
Teaching
Academic Interests and Focus
Teaching Areas
pharmacogenetics and pharmacogenomics